DVAX

Dynavax Technologies Corporation

15.49

USD

DVAX Earnings Reports

Positive Surprise Ratio

DVAX beat 23 of 40 last estimates.

57%

Next Report

Date of Next Report

Feb 18, 2026

Estimate for Q4 25 (Revenue/ EPS)

$81.87M

$0.03

Implied change from Q3 25 (Revenue/ EPS)

-13.71%

-85.71%

Implied change from Q4 24 (Revenue/ EPS)

+15.22%

-40.00%

Dynavax Technologies Corporation earnings per share and revenue

On Nov 05, 2025, DVAX reported earnings of 0.21 USD per share (EPS) for Q3 25, beating the estimate of 0.12 USD, resulting in a 64.71% surprise. Revenue reached 94.88 million, compared to an expected 95.88 million, with a -1.05% difference. The market reacted with a +6.70% price change (close before vs. close after earnings).

Looking ahead to Q4 25, 5 analysts forecast an EPS of 0.03 USD, with revenue projected to reach 81.87 million USD, implying an decrease of -85.71% EPS, and decrease of -13.71% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Amgen Inc

Report Date

Feb 03, 2026 For Q4 25

Estimate

$4.82

Actual

$5.29

Surprise

+9.56%

Bristol-Myers Squibb Co.

Report Date

Feb 05, 2026 For Q4 25

Estimate

$1.12

Actual

$1.26

Surprise

+11.88%

GSK plc - ADR

Report Date

Feb 04, 2026 For Q4 25

Estimate

$0.23

Actual

$0.49

Surprise

+111.36%

Biogen Inc. Common Stock

Report Date

Feb 06, 2026 For Q4 25

Estimate

$1.62

Actual

$1.99

Surprise

+22.39%

Illumina Inc

Report Date

Feb 05, 2026 For Q4 25

Estimate

$1.24

Actual

$1.35

Surprise

+8.01%

QIAGEN N.V.

Report Date

Feb 04, 2026 For Q4 25

Estimate

$0.64

Actual

$0.62

Surprise

-3.32%

Bio-Techne Corp.

Report Date

Feb 04, 2026 For Q2 26

Estimate

$0.44

Actual

$0.46

Surprise

+3.95%

Arrowhead Research Corporation

Report Date

Feb 05, 2026 For Q1 26

Estimate

$0.25

Actual

$0.22

Surprise

-14.76%

Immunovant, Inc. Common Stock

Report Date

Feb 06, 2026 For Q3 26

Estimate

-$0.72

Actual

-$0.61

Surprise

+16.27%

Adaptive Biotechnologies Corporation Common Stock

Report Date

Feb 05, 2026 For Q4 25

Estimate

-$0.18

Actual

-$0.09

Surprise

+51.33%

FAQ

What were Dynavax Technologies Corporation's earnings and revenue for the latest quarter Q3 2025?

For Q3 2025, Dynavax Technologies Corporation reported EPS of $0.21, beating estimates by 64.71%, and revenue of $94.88M, -1.05% below expectations.

How did the market react to Dynavax Technologies Corporation's Q3 2025 earnings?

The stock price moved up 6.7%, changed from $10.30 before the earnings release to $10.99 the day after.

When is Dynavax Technologies Corporation expected to report next?

The next earning report is scheduled for Feb 18, 2026.

What are the forecasts for Dynavax Technologies Corporation's next earnings report?

Based on 5 analysts, Dynavax Technologies Corporation is expected to report EPS of $0.03 and revenue of $81.87M for Q4 2025.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.